Sareum Holdings Plc engages in the discovery and development of drug candidates for the treatment of cancers and autoimmune diseases. Its drug discovery pipeline includes Chk1, TYK2, and Aurora+FLT3 kinases. The company was founded by Timothy John Mitchell, David Hugh Williams, and John Charles Reader on August 1, 2003 and is headquartered in Cambridge, the United Kingdom.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company